The pharmacotherapeutic management of nail unit and acral melanomas

Area of Science:

• Oncology
• Dermatology
• Melanoma Research

Background:

• Acral and nail unit melanomas are rare melanoma subtypes with poor prognoses.
• Optimal treatment guidelines are currently lacking for these specific melanoma types.
• Limited research exists for acral and nail unit melanomas compared to cutaneous melanoma.

Purpose of the Study:

• To provide a comprehensive literature review on treatment options for acral and nail unit melanomas.
• To evaluate the safety and tolerability of current and emerging therapies.
• To identify gaps in research and suggest future directions for clinical trials.

Main Methods:

• Literature review of available treatment options for acral and nail unit melanomas.
• Analysis of safety and tolerability data from clinical studies.
• Synthesis of expert opinions on current therapeutic strategies.

Main Results:

• Programmed cell death protein 1 (PD-1) inhibitors are more effective than cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blockers for acral and nail unit melanomas.
• Both PD-1 and CTLA-4 inhibitors demonstrate good tolerability.
• Tyrosine kinase inhibitors show clinical activity, but safety data is limited.

Conclusions:

• PD-1 inhibitors represent a promising treatment avenue for acral and nail unit melanomas.
• Further investigation into the efficacy and safety of high-dose interferon α-2b and CDK4/6 inhibitors is warranted.
• Prospective, large-scale international clinical trials are essential for advancing treatment strategies.